View in EDS

SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML.

Saved in:
Bibliographic Details
Title: SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3-ITD-mutant AML.
Authors: Pacharne S; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Dovey OM; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Cooper JL; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Gu M; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Friedrich MJ; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany., Rajan SS; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; United Kingdom Dementia Research Institute, University of Cambridge, Cambridge, United Kingdom., Barenboim M; Department of Pediatrics and Children's Cancer Research Center, Klinikum Rechts der Isar, Technical University of Munich, School of Medicine, Munich, Germany., Collord G; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Vijayabaskar MS; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Ponstingl H; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., De Braekeleer E; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Bautista R; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom., Mazan M; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Research and Development Department, Selvita S.A., Krakow, Poland., Rad R; Department of Medicine II, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany.; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; and., Tzelepis K; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Gurdon Institute.; Department of Pathology, and., Wright P; Department of Pathology, and., Gozdecka M; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom., Vassiliou GS; Wellcome Sanger Institute, Wellcome Genome Campus, Cambridge, United Kingdom.; Wellcome-Medical Research Center (MRC) Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom.; Department of Haematology, Cambridge University Hospitals National Health Service (NHS) Trust, Cambridge, United Kingdom.
Source: Blood advances [Blood Adv] 2021 May 11; Vol. 5 (9), pp. 2412-2425.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2020003443